Phase 1 trial reveals high complete response rates with lisocabtagene maraleucel in relapsed mantle cell lymphoma, indicating deep efficacy and manageable toxicity in high-risk disease.
Liso-cel demonstrated high CR rate and deep, durable responses with low incidence of grade ≥3 CRS, NE, and infections in patients with heavily pretreated R/R MCL, including those with high-risk, aggressive disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: